Development of novel antibiotics that inhibit glutamate racemase as transition state analogues
| Project/Area Number |
20790100
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Drug development chemistry
|
|---|
| Research Institution | Gifu Pharmaceutical University |
|---|
Principal Investigator |
OKUDA Kensuke Gifu Pharmaceutical University, 薬学部, 講師 (00311796)
|
|---|
| Project Period (FY) |
2008 – 2009
|
| Project Status |
Completed (Fiscal Year 2009)
|
| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2009: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2008: ¥3,120,000 (Direct Cost: ¥2,400,000、Indirect Cost: ¥720,000)
|
|---|
| Keywords | 遷移状態類縁体 / フッ素 / 抗菌活性 / グルタミン酸 / 抗生物質 |
|---|
| Research Abstract |
Emerging and increasing of multidrug resistant bacteria has become an even more serious issue. In this regard, I pointed the aim at glutamate racemase inhibition, which is an essential enzyme for bacteria, as a novel drug target. As human do not have this enzyme, one can expect that inhibitors of this enzyme do not have side effects. I designed and synthesized substrate analogues as potential inhibitors based on their action mechanism. Actually, one compound showed some antimicrobial activity on S. pneumoniae.
|
Report
(3 results)
Research Products
(5 results)
